Redeye’s initial take on the covid-19 data presented this morning is balanced. In our view, the study indicates that treatment with C21 has a positive effect on several clinical endpoints, which could merit further clinical development in the covid-19 indication. However, we would like information on the primary outcome measurement in the trial, change from baseline in C-reactive protein (CRP). Vicore will host a webcast at 15.00 CET today, where we hope to gain further visibility into the study results. We aim to gather more information on the data package and get back with an updated view.